Celaid Therapeutics implemented a third-party allotment of shares with The University of Tokyo Edge Capital Partners Co., Ltd. (Bunkyo-ku, Tokyo, President and Managing Partner, Tomotaka Goji).
This capital procurement will promote the development of our technologies and will allow us to accelerate the development of new therapies.